trial

Modafinil Effects on Cognition in Schizophrenia Patients

NCTId NCT00711464
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 29 (actual)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2012-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
29 (actual)
Study type
Interventional
Allocation
Randomized
Model
Single Group
Masking
Quadruple
Start
2008-05
Primary completion
2012-07
Eligibility
ALL · 18 Years · 54 Years

Interventions & indications

Drugs
modafinil (M1, M2, M4)

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor

Investigators

1
Michael J. Minzenberg, MDPrincipal Investigator

Sites

2 total
Los Angeles, United StatesSacramento, United States

Facts & assertions

4 sourced
Enrollment
29
Phase
PHASE4
Primary Completion Date
2012-07
Status
COMPLETED
relationships
The graph out of here
drug
modafinil (M1, M2, M4)
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Michael J. Minzenberg, MD
person